Smoking and Obesity Interact to Adversely Affect Disease Progression and Cognitive Performance in Multiple Sclerosis

IF 3.9 2区 医学 Q1 CLINICAL NEUROLOGY European Journal of Neurology Pub Date : 2025-02-04 DOI:10.1111/ene.70058
Johansson Eva, Tomas Olsson, Lars Alfredsson, Anna Karin Hedström
{"title":"Smoking and Obesity Interact to Adversely Affect Disease Progression and Cognitive Performance in Multiple Sclerosis","authors":"Johansson Eva,&nbsp;Tomas Olsson,&nbsp;Lars Alfredsson,&nbsp;Anna Karin Hedström","doi":"10.1111/ene.70058","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Smoking and obesity interact to exacerbate the risk of hypertension, diabetes, and cardiovascular disease, but their potential synergistic effects on outcomes in multiple sclerosis (MS) have not been well studied. We aimed to study whether smoking and obesity interact to affect disease progression and cognitive function in patients with MS.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Incident cases from the population-based case–control study Epidemiological Investigation of MS (EIMS) were categorized by smoking and obesity status at diagnosis and followed up to 15 years postdiagnosis through the Swedish MS registry (<i>n</i> = 3336). Cox regression was used to analyze outcomes, including clinical disease worsening (CDW), progression to Expanded Disability Status Scale (EDSS) levels 3 and 4, physical worsening as measured by a 7.5-point increase in the MS Impact Scale (MSIS) physical score, and cognitive decline, defined as an 8-point or greater reduction on the Symbol Digit Modalities Test (SDMT). Interaction effects on the additive scale were assessed by combining dichotomous variables for smoking (nonsmoker = 0, smoker = 1) and obesity (nonobese = 0, obese = 1), yielding four categories: 0/0 (reference category), 0/1, 1/0, and 1/1.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Additive interactions between smoking and obesity were identified for CDW (attributable proportion due to interaction [AP] 0.18, 95% CI 0.03–0.30), progression to EDSS 4 (AP 0.18, 95% CI 0.08–0.26), MSIS-Physical score worsening (AP 0.32, 95% CI 0.21–0.42), and cognitive decline (AP 0.27, 95% CI 0.19–0.35).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Smoking and obesity appear to synergistically worsen MS progression and cognitive functioning, with the observed additive interactions across most outcomes suggesting that these factors partly share common biological pathways contributing to disease progression.</p>\n </section>\n </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"32 2","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.70058","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ene.70058","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Smoking and obesity interact to exacerbate the risk of hypertension, diabetes, and cardiovascular disease, but their potential synergistic effects on outcomes in multiple sclerosis (MS) have not been well studied. We aimed to study whether smoking and obesity interact to affect disease progression and cognitive function in patients with MS.

Methods

Incident cases from the population-based case–control study Epidemiological Investigation of MS (EIMS) were categorized by smoking and obesity status at diagnosis and followed up to 15 years postdiagnosis through the Swedish MS registry (n = 3336). Cox regression was used to analyze outcomes, including clinical disease worsening (CDW), progression to Expanded Disability Status Scale (EDSS) levels 3 and 4, physical worsening as measured by a 7.5-point increase in the MS Impact Scale (MSIS) physical score, and cognitive decline, defined as an 8-point or greater reduction on the Symbol Digit Modalities Test (SDMT). Interaction effects on the additive scale were assessed by combining dichotomous variables for smoking (nonsmoker = 0, smoker = 1) and obesity (nonobese = 0, obese = 1), yielding four categories: 0/0 (reference category), 0/1, 1/0, and 1/1.

Results

Additive interactions between smoking and obesity were identified for CDW (attributable proportion due to interaction [AP] 0.18, 95% CI 0.03–0.30), progression to EDSS 4 (AP 0.18, 95% CI 0.08–0.26), MSIS-Physical score worsening (AP 0.32, 95% CI 0.21–0.42), and cognitive decline (AP 0.27, 95% CI 0.19–0.35).

Conclusions

Smoking and obesity appear to synergistically worsen MS progression and cognitive functioning, with the observed additive interactions across most outcomes suggesting that these factors partly share common biological pathways contributing to disease progression.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
吸烟和肥胖相互作用对多发性硬化症的疾病进展和认知能力产生不利影响
吸烟和肥胖相互作用会加剧高血压、糖尿病和心血管疾病的风险,但它们对多发性硬化症(MS)预后的潜在协同效应尚未得到很好的研究。我们的目的是研究吸烟和肥胖是否相互作用影响MS患者的疾病进展和认知功能。方法来自基于人群的病例对照研究MS流行病学调查(EIMS)的事件病例根据诊断时的吸烟和肥胖状况进行分类,并通过瑞典MS登记处(n = 3336)随访至诊断后15年。使用Cox回归分析结果,包括临床疾病恶化(CDW),扩展残疾状态量表(EDSS) 3级和4级的进展,MS影响量表(MSIS)身体评分增加7.5分测量的身体恶化,以及认知能力下降,定义为符号数字模式测试(SDMT)减少8分或更多。通过结合吸烟(非吸烟者= 0,吸烟者= 1)和肥胖(非肥胖= 0,肥胖= 1)的二分类变量来评估加性量表的相互作用效应,得出4个类别:0/0(参考类别)、0/1、1/0和1/1。结果吸烟和肥胖之间的相互作用被确定为CDW(归因于相互作用的比例[AP] 0.18, 95% CI 0.03-0.30),进展到EDSS 4 (AP 0.18, 95% CI 0.08-0.26), msis -身体评分恶化(AP 0.32, 95% CI 0.21-0.42)和认知能力下降(AP 0.27, 95% CI 0.19-0.35)。吸烟和肥胖似乎协同恶化MS进展和认知功能,在大多数结果中观察到的加性相互作用表明,这些因素在一定程度上具有共同的促进疾病进展的生物学途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European Journal of Neurology
European Journal of Neurology 医学-临床神经学
CiteScore
9.70
自引率
2.00%
发文量
418
审稿时长
1 months
期刊介绍: The European Journal of Neurology is the official journal of the European Academy of Neurology and covers all areas of clinical and basic research in neurology, including pre-clinical research of immediate translational value for new potential treatments. Emphasis is placed on major diseases of large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases).
期刊最新文献
Gene–Environment Interactions for Alzheimer's Disease Pathology in Cognitively Normal Adults: The CABLE Study Mortality From Amyotrophic Lateral Sclerosis in Finland 1987–2022 Older Adults, Anti-Amyloid Therapy, and Frailty: What Oncology Can Teach Us Palliative Care in Europe: Safeguarding Compassion Amidst Changing End-of-Life Policies and Expanding Access to Medically Assisted Dying Position Statement on behalf of the European Academy of Neurology, the European Federation of Neurological Associations and OneNeurology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1